4,4'-설포닐디아닐린
|
|
4,4'-설포닐디아닐린 속성
- 녹는점
- 175-177 °C(lit.)
- 끓는 점
- 511.7±35.0 °C(Predicted)
- 밀도
- 1.2701 (rough estimate)
- 증기압
- 0.004Pa at 25℃
- 굴절률
- 1.5950 (estimate)
- 저장 조건
- 2-8°C
- 용해도
- 0.38g/L
- 물리적 상태
- 결정성 분말
- 산도 계수 (pKa)
- pKb 13.0(at 25℃)
- 색상
- 흰색에서 베이지색
- 수소이온지수(pH)
- 5.5-7.5 (H2O, 20℃)(saturated aqueous solution)
- 수용성
- 20°C에서 <0.1g/100mL
- Merck
- 14,2822
- BRN
- 788055
- BCS Class
- 4,2
- 안정성
- 안정적인. 타기 쉬운. 강한 산화제와 호환되지 않습니다.
- InChIKey
- MQJKPEGWNLWLTK-UHFFFAOYSA-N
- LogP
- 0.97 at 25℃
- CAS 데이터베이스
- 80-08-0(CAS DataBase Reference)
- NIST
- Dapsone(80-08-0)
- IARC
- 3 (Vol. 24, Sup 7) 1987
안전
- 위험 및 안전 성명
- 위험 및 사전주의 사항 (GHS)
위험품 표기 | Xn | ||
---|---|---|---|
위험 카페고리 넘버 | 22 | ||
안전지침서 | 22 | ||
유엔번호(UN No.) | 3249 | ||
WGK 독일 | 1 | ||
RTECS 번호 | BY8925000 | ||
TSCA | Yes | ||
위험 등급 | 6.1(b) | ||
포장분류 | III | ||
HS 번호 | 29051620 | ||
HS 번호 | 29309070 | ||
유해 물질 데이터 | 80-08-0(Hazardous Substances Data) | ||
독성 | LD50 orally in Rabbit: 1000 mg/kg LD50 dermal Rabbit > 4000 mg/kg | ||
기존화학 물질 | KE-09736 |
4,4'-설포닐디아닐린 C화학적 특성, 용도, 생산
화학적 성질
Off -White Crystalline Solid용도
4,4'-diaminodiphenylsulfone be used for preparation polyimide and epoxy resin material.Indications
Although dapsone (Avlosulfon) is most often used as an antimicrobial agent, it has important antiinflammatory properties in many noninfectious skin diseases. The mechanism of action of dapsone in skin disease is not clear.Most of the cutaneous diseases for which it is effective manifest inflammation and are characterized by an infiltration of neutrophils; the drug’s antiinflammatory effect may arise from its inhibition of intracellular neutrophil reactions mediated by myeloperoxidase and hydrogen peroxide or from its scavenging of reactive oxygen species, which inhibits inflammation.정의
ChEBI: A sulfone that is diphenylsulfone in which the hydrogen atom at the 4 position of each of the phenyl groups is substituted by an amino group. It is active against a wide range of bacteria, but is mainly employed for its actions against Mycobacteriu leprae, being used as part of multidrug regimens in the treatment of all forms of leprosy.Antimicrobial activity
Dapsone is active against many bacteria and some protozoa. Fully susceptible strains of M. leprae are inhibited by a little as 0.003 mg/L. It is predominantly bacteristatic. Resistance is associated with mutations in the folP1 gene involved in the synthesis of para-aminobenzoic acid.원료
Resistance to high levels is acquired by several sequential mutations. As a result of prolonged use of dapsone monotherapy, acquired resistance emerged in patients with multibacillary leprosy in many countries. Initial resistance also occurs in patients with both paucibacillary and multibacillary leprosy. Thus, leprosy should always be treated with multidrug regimens. Resistance of M. leprae to dapsone (and other anti-leprosy drugs) may now be determined by use of DNA microarrays.일반 설명
Odorless white or creamy white crystalline powder. Slightly bitter taste.공기와 물의 반응
Sensitive to oxidation and light. Insoluble in water.반응 프로필
4,4'-Diaminodiphenylsulfone can neutralize acids in exothermic reactions to form salts plus water. May be incompatible with isocyanates, halogenated organics, peroxides, phenols (acidic), epoxides, anhydrides, and acid halides. Flammable gaseous hydrogen is generated in combination with strong reducing agents, such as hydrides. Incompatible with strong oxidizing agents. Also incompatible with epoxy resins under uncontrolled conditions .화재위험
4,4'-Diaminodiphenylsulfone is probably combustible.Pharmaceutical Applications
The most effective of a number of sulfonamide derivatives to be tested against leprosy. The dry powder is very stable. It is only slightly soluble in water.Pharmacokinetics
Oral absorption: >90%Cmax 100 mg oral: c. 2 mg/L after 3–6 h
Plasma half-life: 10–50 h
Plasma protein binding: c. 50%
It is slowly but almost completely absorbed from the intestine and widely distributed in the tissues, but selectively retained in skin, muscle, kidneys and liver. It is metabolized by N-oxidation and also by acetylation, which is subject to the same genetic polymorphism as isoniazid. The elimination half-life is consequently very variable, but on standard therapy the trough levels are always well in excess of inhibitory concentrations. It is mostly excreted in the urine: in the unchanged form (20%), as N-oxidation products (30%) and as a range of other metabolites.
Clinical Use
Leprosy (multidrug regimens)Prophylaxis of malaria, treatment of chloroquine-resistant malaria (in combination with pyrimethamine)
Prophylaxis of toxoplasmosis (in combination with pyrimethamine)
Prophylaxis (monotherapy) and treatment (in combination with trimethoprim) of Pneumocystis jirovecii pneumonia
Dermatitis herpetiformis and related skin disorders
부작용
Although usually well tolerated at standard doses, gastrointestinal upsets, anorexia, headaches, dizziness and insomnia may occur. Less frequent reactions include skin rashes, exfoliative dermatitis, photosensitivity, peripheral neuropathy (usually in non-leprosy patients), tinnitus, blurred vision, psychoses, hepatitis, nephrotic syndrome, systemic lupus erythematosus and generalized lymphadenopathy.The term ‘dapsone syndrome’ is applied to a skin rash and fever occurring 2–8 weeks after starting therapy and sometimes accompanied by lymphadenopathy, hepatomegaly, jaundice and/or mononucleosis.
Blood disorders include anemia, methemoglobinemia, sulfhemoglobinemia, hemolysis (notably in patients with glucose- 6-phosphate dehydrogenase deficiency), mononucleosis, leukopenia and, rarely, agranulocytosis. Severe anemia should be treated before patients receive dapsone.
The incidence of adverse reactions declined in the 1960s but reappeared around 1982 when multidrug therapy was introduced, and may represent an unexplained interaction with rifampicin.
Safety Profile
Poison by ingestion, intraperitoneal, and subcutaneous routes. Human systemic effects by ingestion: agranulocytosis, change in tubules and other kidney changes, cyanosis, effect on joints, hemolysis with or without anemia, jaundice, methemoglobinemiacarboxyhemoglobinemia, retinal changes, somnolence. Experimental reproductive effects. Can cause hepatitis, dermatitis, and neuritis. Questionable carcinogen with experimental carcinogenic and neoplastigenic data. Human mutation data reported. Used in leprosy treatment and veterinary medicine. When heated to decomposition it emits very toxic fumes of NOx and SOx. See also SULFONATES.4,4'-설포닐디아닐린 준비 용품 및 원자재
원자재
준비 용품
4,4'-설포닐디아닐린 공급 업체
글로벌( 734)공급 업체
공급자 | 전화 | 이메일 | 국가 | 제품 수 | 이점 |
---|---|---|---|---|---|
Chengdu Yuanda Chemical Co., Ltd | 28-85356300 +8618980937689 |
sales@ydachem.com | CHINA | 94 | 58 |
Hebei Mojin Biotechnology Co., Ltd | +86 13288715578 +8613288715578 |
sales@hbmojin.com | China | 12446 | 58 |
Hebei Yanxi Chemical Co., Ltd. | +8617531190177 |
peter@yan-xi.com | China | 5873 | 58 |
Hebei Chuanghai Biotechnology Co,.LTD | +86-13131129325 |
sales1@chuanghaibio.com | China | 5882 | 58 |
Hebei Fengjia New Material Co., Ltd | +86-0311-87836622 +86-17333973358 |
sales06@hbduling.cn | China | 8056 | 58 |
Henan Fengda Chemical Co., Ltd | +86-371-86557731 +86-13613820652 |
info@fdachem.com | China | 20293 | 58 |
Hangzhou Hyper Chemicals Limited | +86-0086-57187702781 +8613675893055 |
info@hyper-chem.com | China | 295 | 58 |
Hebei Zhuanglai Chemical Trading Co.,Ltd | +8613343047651 |
admin@zlchemi.com | China | 3002 | 58 |
Watson Biotechnology Co.,Ltd | +86-18186686046 +86-18186686046 |
sales01@watsonbiotech.cn | China | 5851 | 58 |
Capot Chemical Co.,Ltd. | 571-85586718 +8613336195806 |
sales@capotchem.com | China | 29798 | 60 |
4,4'-설포닐디아닐린 관련 검색:
4,4'-메틸렌디아닐린 디페닐술폰 4,4'-설포닐다이페놀 3,4-디아미노벤조페논 비스(4-아미노페닐) 에테르 4-클로로페닐 2,4,5-트라이클로로페닐 설폰 4,4'-디클로로디페닐 술폰 4,4'-설포닐디아닐린
3,4'-DIAMINODIPHENYLMETHANE
Phenyl sulfoxide
solasulfone
BIS(4-NITROPHENYL) SULFONE
ISOTHIOCYANATOPHENYL SULFONE
DAPSONE HYDROXYLAMINE
Amidapsone
4-[[4-[(4-aminophenyl)sulphonyl]phenyl]amino]-4-oxobutyric acid
Aldesulfone Sodium
3,3'-Sulfonyldianiline